Targeting the PI3K-Akt-mTOR axis in AML presents a particular challenge, as its dysregulation is not only driven by leukemic cell-intrinsic factors but also by cues from the microenvironment, including MSCs and immune cells (141). The gene discussed is MTOR; the disease is acute myeloid leukemia.